about
Pulsed High-Intensity Focused Ultrasound Enhances Delivery of Doxorubicin in a Preclinical Model of Pancreatic Cancer.Usability evaluation of pharmacogenomics clinical decision support aids and clinical knowledge resources in a computerized provider order entry system: a mixed methods approach.Topotecan disposition in an anephric child.A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.Efficient and stable MGMT-mediated selection of long-term repopulating stem cells in nonhuman primates.Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantationPotential contribution of cytochrome P450 2B6 to hepatic 4-hydroxycyclophosphamide formation in vitro and in vivoCurrent status of cetuximab for the treatment of patients with solid tumors.Assessment of ovarian failure and osteoporosis in premenopausal breast cancer survivors.Making pharmacogenomic-based prescribing alerts more effective: A scenario-based pilot study with physicians.Glucocorticoids and insulin resistance in children with acute lymphoblastic leukemia.Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Immunosuppressants in Allogeneic Hematopoietic Cell Transplantation: Part II.Pharmacokinetics, Pharmacodynamics and Pharmacogenomics of Immunosuppressants in Allogeneic Haematopoietic Cell Transplantation: Part IFluconazole coadministration concurrent with cyclophosphamide conditioning may reduce regimen-related toxicity postmyeloablative hematopoietic cell transplantation.Population pharmacokinetics of cyclophosphamide and metabolites in children with neuroblastoma: a report from the Children's Oncology GroupVariation in prescribing patterns and therapeutic drug monitoring of intravenous busulfan in pediatric hematopoietic cell transplant recipientsEstablishment of long-term tolerance to SRBC in dogs by recombinant canine CTLA4-Ig.A limited sampling schedule to estimate individual pharmacokinetic parameters of fludarabine in hematopoietic cell transplant patients.Cyclophosphamide followed by intravenous targeted busulfan for allogeneic hematopoietic cell transplantation: pharmacokinetics and clinical outcomesBusulfan in hematopoietic stem cell transplant setting.Busulfan in infant to adult hematopoietic cell transplant recipients: a population pharmacokinetic model for initial and Bayesian dose personalization.Health care use and primary prophylaxis with colony-stimulating factors.Optimizing drug therapy in pediatric SCT: focus on pharmacokinetics.Personalizing Busulfan-Based Conditioning: Considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee.A novel phenotypic method to determine fludarabine triphosphate accumulation in T-lymphocytes from hematopoietic cell transplantation patients.Colony-stimulating factor use and impact on febrile neutropenia among patients with newly diagnosed breast, colorectal, or non-small cell lung cancer who were receiving chemotherapy.Real-time dose adjustment of cyclophosphamide in a preparative regimen for hematopoietic cell transplant: a Bayesian pharmacokinetic approach.Development of a population pharmacokinetics-based sampling schedule to target daily intravenous busulfan for outpatient clinic administration.A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease.Measured versus estimated glomerular filtration rate in the Calvert equation: influence on carboplatin dosing.Lack of gender differences and large intrasubject variability in cytochrome P450 activity measured by phenotyping with dextromethorphan.The effect of cyclophosphamide with and without dexamethasone on cytochrome P450 3A4 and 2B6 in human hepatocytes.Developing and Using Therapeutics for Emerging Infections.Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation.Physiologically based pharmacokinetic modelling of Busulfan: a new approach to describe and predict the pharmacokinetics in adults.Predictive performance of a physiologically based pharmacokinetic model of busulfan in children.Influence of age upon Ifosfamide-induced nephrotoxicity.Intraindividual variability in busulfan pharmacokinetics in patients undergoing a bone marrow transplant: assessment of a test dose and first dose strategy.The cost of adjuvant chemotherapy in patients with early-stage breast carcinoma.Contribution of CYP3A5 to hepatic and renal ifosfamide N-dechloroethylation.
P50
Q27347648-91BE6225-C53A-4816-94B6-7C9FD51D19DAQ28540676-FDA342A7-E670-489B-B387-FC20CA8C2CC5Q33362406-2D10F761-9A76-49B7-A204-FA5CE3A8B311Q33368776-82824A3F-1198-4EFA-B62F-77C613DE7152Q33968014-B6E7E09C-2A61-45F0-9B09-7A880F5CB394Q35184589-C9BD46A0-DE89-4EED-A919-444D021085DFQ35647150-B6D00B12-4B44-48BD-B0D8-EE07BE7598FCQ36364973-2C2A7CDB-39AA-4A0F-8882-E11161C9DDD7Q36388020-AB2364E1-9130-4CAF-8FB4-1FCA003B9F0EQ36438790-C42E4266-45D9-42A2-BBB3-B8AC529DF014Q36598564-2F072374-BE66-40C7-90E5-BCE6C6D19C0FQ36777485-F8D55D7E-B604-4CEE-ADD0-95200FF88848Q36777599-B182206B-459B-44D0-8302-4413ED3FB52AQ36949557-49F0EE73-11C3-40A4-BD37-913AB233E3FAQ37120672-17DB1C4E-46D1-43B5-93E1-ADA371E4AF8CQ37224427-039E7A9A-5422-440D-A88F-2B76C958D166Q37366120-B83A74D4-B459-45F6-BD5D-BB703CA0040AQ37390905-984AD4B7-63EB-4BC4-939F-715BD6CA3E87Q37504482-52B9CB5E-304D-447C-AAF9-598866666E0DQ37554387-75604942-C231-4527-8AB5-21D10801746EQ37624344-64D9D632-140E-41EC-AF61-6D3AA4439BD6Q37852866-61BAC032-D98B-447C-9D57-09F87B65790EQ38262916-42CD7950-6078-4B02-A779-8CFA3194A1D5Q38915625-C4D8E2FA-B84B-49B0-989E-2E0E7507AC51Q39993836-ED5F3FB9-14E4-402F-97F0-82B84CAE7FEEQ40294108-5B87F329-2B00-4703-9D81-E0F23428574FQ42595554-1CF3FB67-66CF-4261-B4D8-AC756C041081Q43194170-5F0A1FE2-682D-4B9F-A2C3-CF7756DE89BFQ43405471-EFFCC545-6761-4ABD-8AE1-92E0179243FCQ43629723-37CA607B-5B87-48BB-8548-AC44BC16B6BAQ43673452-C9D88AFF-1E29-4DBC-B14F-799AB3042599Q44028572-C79007A1-F917-41AD-8AA3-C710B169FE92Q44099540-9D9D0EC2-3525-4919-85E3-8D16B2D7E373Q44110270-74DEBF72-41FA-4330-929E-2415EE3A7BC3Q44395207-AFE9D8B5-D026-4FB6-855A-A9FF087B70CEQ44419087-B7600D9A-2DEA-4E91-BE35-634E6E712636Q44817689-DA6DE664-3AB9-4C5E-97C5-BDAEB7688AE2Q44913185-42FFE30E-09FC-4B0D-874D-5EF5D397FDCAQ46271859-2C5D65A9-FCC0-40B5-AA7E-C6BCA1C4704DQ46430447-2938AEE9-D636-4EBE-8178-2AED0E9FBC66
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Jeannine S McCune
@nl
Jeannine S McCune
@sl
Jeannine S. McCune
@en
Jeannine S. McCune
@es
type
label
Jeannine S McCune
@nl
Jeannine S McCune
@sl
Jeannine S. McCune
@en
Jeannine S. McCune
@es
prefLabel
Jeannine S McCune
@nl
Jeannine S McCune
@sl
Jeannine S. McCune
@en
Jeannine S. McCune
@es
P106
P1153
7006305215
P21
P31
P496
0000-0002-0795-497X